Navigation Links
Gene therapy could expand stem cells' promise
Date:5/21/2009

Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician.

But gene therapy has the potential to solve this problem, according to a perspective article from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center published in a recent issue of the journal Cell Stem Cell. The paper details strategies for genetically modifying stem cells prior to transplantation in order to ensure their safety.

"Stem cell therapy offers enormous potential to treat and even cure serious diseases. But wayward stem cells can turn into a runaway train without a conductor. This is an issue that can be dealt with and we have the technology to do that in the form of gene therapy," says senior author Dr. Ronald G. Crystal, chief of the Division of Pulmonary and Critical Care Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Bruce Webster Professor of Internal Medicine and Professor of Genetic Medicine at Weill Cornell Medical College.

Stem cells have the capacity to differentiate into any of the different tissues making up the human body, thus holding the promise of treating or curing diseases such as multiple sclerosis or spinal-cord injury by replacing diseased cells with healthy cells.

But unlike other therapies such as chemotherapy, antibiotics or aspirin, stem cells have no expiration date, and that poses a real problem.

"Almost all therapeutics we use have a half life. They only last a certain amount of time," Dr. Crystal says. "Stem cells are the opposite. Once the future stem cell therapist does the therapy, stem cells have the innate potential to produce more cells."

The challenge takes on even more urgency with recent developments, including a federal administration now more open to exploring the potential of stem cells, the recent FDA approval of a human trial involving embryonic stem cells, as well as the reported case of a young boy who developed a brain tumor four years after receiving a stem-cell treatment for a rare genetic disorder.

As evidenced by this boy's experience, one of the biggest potential problems with stem cell therapy is the development of tumors.

But there are other problems as well.

Stem cells directed to become beating heart cells might mistakenly end up in the brain. Or insulin-producing beta cells which can't stop means the body can no longer regulate insulin levels.

"You've totally lost control," Dr. Crystal says. "What do you do?"

The best chance of circumventing these issues is genetic modification of the stem cells prior to actually transplanting them, Dr. Crystal says. Theoretically, this is similar to how gene therapy is used to treat cancer, but with important improvements.

"Instead of gene therapy being done in the patient, as is the case in cancer, it's being done in the cells in a laboratory before doctors use them for therapy so that they still have control of these cells," Dr. Crystal explains.

Therapists would rig certain genes to respond to a "remote control" signal. For instance, giving a certain drug could prompt a "suicide" gene to kill a budding tumor.

But gene therapy also needs to be carefully done and, ideally, two independent gene-manipulation systems would be used to ensure that stem cells remain firmly in control of clinicians.


'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related biology news :

1. Breakthrough in radiotherapy promises targeted cancer treatment
2. From cars to cancer: UH professor employs auto industry tools for tumor therapy
3. Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
4. Moving gene therapy forward with mobile DNA
5. Simulated gene therapy
6. Early administration of antiretroviral therapy can improve survival
7. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
8. Gene therapy appears safe to regenerate gum tissue
9. Two-day symposium in Baltimore to tackle the promises and perils of proton radiotherapy
10. CSHL team develops mouse models of leukemia that predict response to chemotherapy
11. Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:2/1/2016)... -- Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of a new ... Las Vegas , where Joey appeared at the ... Las Vegas , where Joey appeared at the Wocket booth to ... was filmed at the Consumer Electronics Show (CES2016) in Las ... and greet fans. --> --> ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, ... of the Highest Overall Customer Rating Award from Circuits Assembly , today announced ... across the USA, Canada, Mexico and China. , The EMS provider, known in ...
(Date:2/9/2016)... , Feb. 9, 2016  Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative ... tissues and organs, recently reported the Company,s operating ... quarter of 2016. Lonza America , ... 2015 fiscal year in the process of consummating ...
(Date:2/9/2016)... ... February 08, 2016 , ... ... announced today the launch of its revamped and improved website. In an on-going ... solutions, the redesigned website will better communicate how the company designs and delivers ...
(Date:2/9/2016)... ... 2016 , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre has joined the ... acquiring new accounts and work closely with existing Tunnell clients throughout Europe to ensure ... European clients more than 15 years of experience in the pharmaceutical industry, a thorough ...
Breaking Biology Technology: